A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease
Latest Information Update: 16 Jun 2025
At a glance
- Drugs RO-7269162 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 14 Oct 2026 to 30 Nov 2026.
- 10 Jun 2025 Planned primary completion date changed from 14 Oct 2026 to 30 Nov 2026.
- 10 Jun 2025 Status changed from recruiting to active, no longer recruiting.